ACM
VERV

ADAR1 Capital Management’s Verve Therapeutics VERV Stock Holding History

ADAR1 Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-469,018
Closed -$5.27M – 264
2025
Q2 		$5.27M Buy
+469,018
New +$2.67M 0.81% 33
2024
Q3 		– Sell
-44,000
Closed -$215K – 344
2024
Q2 		$215K Buy
+44,000
New +$277K 0.04% 139

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

ADAR1 Capital Management's VERV Position: Q3 2025 in Review

ADAR1 Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 469,018 shares — an estimated $5.27M sold.

ADAR1 Capital Management first reported a position in VERV in Q2 2024 and held it in 2 quarters. The position peaked at $5.27M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • ADAR1 Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 469,018 Verve Therapeutics shares in Q3 2025, an estimated $5.27M.
  • ADAR1 Capital Management first reported a position in Verve Therapeutics in Q2 2024 and held it in 2 quarters.
  • ADAR1 Capital Management's Verve Therapeutics position peaked at $5.27M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.